Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases, today announced the addition of Vincent Stanton Jr., MD to its Scientific Advisory Board ("SAB"). Dr. Stanton was a co-founder of Thiogenesis Therapeutics, Inc., dating back to February 2016. Dr. Vincent Stanton Jr., MD is an entrepreneur and...
2023-11-27 9:00 AM EST
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement of $4.5 million (the "Offering") through the issuance of 6,000,000 common shares of the Company ("Offered Shares") at a price of $0.75 per Common Share. This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering...
2023-11-20 9:00 AM EST
Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update
San Diego, California--(Newsfile Corp. - May 10, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing thiol-active compounds for unmet pediatric diseases, today reports on full year 2022 financial results and provides a corporate update. Patrice Rioux, M.D., Ph.D., Thiogenesis' founder and Chief Executive Officer stated, "We are pleased to report on a very eventful 2022, including: completing a going public...
2023-05-10 9:00 AM EDT
Thiogenesis Announces Stock Option Grants
San Diego, California--(Newsfile Corp. - December 9, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that it has granted an aggregate of 450,000 incentive stock options (the "Options") pursuant to the Company's stock option plan of which 350,000 were granted to directors and officers and 100,000 to a consultant. Each Option entitles the optionee to acquire one common share of the Company at an exercise price of $0.60 per common share...
2022-12-09 10:00 AM EST
Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - November 21, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce today, further to its news releases of October 24 and November 2, 2022, that it has closed an over-subscribed non-brokered private placement (the "Offering") through the issuance of 10,619,400 common shares (the "Offered Shares") in the capital of the Company for gross proceeds of $5,309,700 at a price of $0.50 per Offered Share. All...
2022-11-21 10:45 AM EST
Thiogenesis Announces Increase in Offering Size for Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - November 2, 2022) - Further to its news release of October 24, 2022, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, due to strong investor demand, it has increased the size of the non-brokered private placement from $4 million to $5.3 million (the "Offering") through the issuance of up to 10,600,000 common shares of the Company ("Offered Shares") at a price of $0.50 per share in the manner...
2022-11-02 7:30 AM EDT
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - October 24, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement to raise up to $4 million (the "Offering") through the issuance of up to 8,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share. This Offering is subject to the approval of the TSX Venture Exchange ("Exchange"). The Company anticipates closing of...
2022-10-24 9:00 AM EDT
Thiogenesis Adopts New Equity Incentive Plan
San Diego, California--(Newsfile Corp. - October 17, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (Thiogenesis or the Company) is pleased to announce that the TSX Venture Exchange (the "Exchange") has accepted for filing, the Company's new incentive stock option plan (the "2022 Plan"). The 2022 Plan replaces the Company's previous 10% rolling stock option plan (the "Old Plan"). The 2022 Plan is a "fixed" plan, such that the aggregate number of common shares that may be issued upon the...
2022-10-17 6:22 PM EDT
Thiogenesis Announces Results from Annual and Special Meeting of Shareholders
San Diego, California--(Newsfile Corp. - September 26, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that shareholders have approved all matters put forward at its Annual and Special Meeting ("ASM") held on September 19th, 2022. All five members of the Company's board of directors, Dr. Patrice Rioux, Dr. Christopher Starr, Kim Tsuchimoto, Hogan Mullally and Brook Riggins, named as nominees in the Company's management information...
2022-09-26 9:30 AM EDT
Thiogenesis Announces the Formation of its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - August 30, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases today announced the formation of its Scientific Advisory Board ("SAB"). The SAB members are acclaimed leaders in their fields and will provide strategic guidance utilizing their vast experience to support the successful clinical and commercial...
2022-08-30 9:00 AM EDT
Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
San Diego, California--(Newsfile Corp. - May 18, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for serious pediatric diseases, today announces positive results from its Phase 1 clinical study of oral TTI-0102 in healthy volunteers in Australia. The Phase 1, "O
2022-05-18 9:00 AM EDT
CORRECTION FROM SOURCE: Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it closed its previously announced Qualifying Transaction (the "QT") as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Thiogenesis Therapeutics, Inc. ("TTI-US") (see the Company's press releases dated March 12, 2021, March 23, 2021, J
2022-04-05 11:19 PM EDT
Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it closed its previously announced Qualifying Transaction (the "QT") as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Thiogenesis Therapeutics, Inc. ("TTI-US") (see the Company's press releases dated March 12, 2021, March 23, 2021, July 27, 2021 and March 21,...
2022-04-05 4:57 PM EDT
Rozdil Capital Corporation Completes Initial Public Offering; Common Shares Commence Trading
Toronto, Ontario--(Newsfile Corp. - July 16, 2019) - Rozdil Capital Corporation (TSXV: ROZ.P) (the "Corporation") is pleased to announce that it has successfully completed its initial public offering of 2,150,000 common shares (the "Common Shares") at $0.10 per share for gross proceeds of $215,000 (the "Offering"). As a result of this issuance, the Corporation has 4,500,000 Common Shares issued and outstanding, of which 2,350,000 Common Shares are subject to escrow restrictions as disclosed...
2019-07-16 9:00 AM EDT